Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the "Board") of SSY Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that Jiangsu Best New Medical Material Co., Ltd. ("Jiangsu Best", a wholly-owned subsidiary in the Group) and Shanghai Lepure Biotech Co., Ltd. (上海樂純生物技術有限公司) ("Party A") entered into a "Strategic Cooperation Memorandum" on 23 July 2021. Both parties agreed to carry out all-round cooperation in areas including research & development, testing and promotion of application of bioprocessing films and related products, and to jointly develop the international and domestic markets of bioprocessing films, so as to strive to maximize the win-win cooperation. Jiangsu Best will add a production line for 1.6 meters-width 7-layers bioprocessing films. Under the condition of meeting the requirements of Party A on product quality and performance, Party A agreed on preemption to purchase products of Jiangsu Best.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board Chow Hing Yeung Company Secretary

Hong Kong, 23 July 2021

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Wang Xianjun and Mr. Su Xuejun as executive Directors, Mr. Feng Hao as non-executive Director and Mr. Wang Yibing, Mr. Leung Chong Shun and Mr. Chow Kwok Wai as independent non-executive Directors.